Microbot Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform
December 14 2017 - 7:00AM
Microbot Medical Inc. (Nasdaq:MBOT), a medical device company
specializing in the design and development of transformational
micro-robotic medical technologies, today announced the U.S. Patent
and Trademark Office (USPTO) has issued a Notice of Allowance
covering the Company’s TipCAT technology platform. This
increases the number of issued or allowed patents to 24 and an
additional 12 patent applications pending worldwide, covering its
ViRob™ and TipCAT™ technology platforms.
“The allowance of this patent is an integral
part of our overall strategy and demonstrates our commitment to
protecting our assets and expanding our IP portfolio, either
organically or externally,” commented Harel Gadot, Chief Executive
Officer, President, and Chairman. “Focusing on the continued
development milestones of our future offering, such as the
significant progress we are making with our self-cleaning shunt
(SCS), combined with strengthening our global IP portfolio allow us
to differentiate our unique products and create barriers of entry
to future competition. I believe that the expected growth of
minimally invasive surgical (MIS) procedures in general, and
specifically the increasing adoption of robotic surgery, will
continue to drive the need for large medical device companies to
acquire and/or collaborate with robotics-focused companies. As
such, I believe today’s allowance and our continued innovation are
value drivers for our shareholders.”
The allowed patent application (Patent App. No.
14/746,660) is a continuation of Patent No. 9,061,118, issued on
June 23, 2015, and covers Microbot’s TipCAT device having a hollow
passageway running through a central region of the device’s set of
inflatable chambers, the passageway being adapted to contain an
element (e.g. a guidewire) threaded inside, such that when
inflated, at least one of the inflatable chambers applies pressure
at the passageway and grips the element threaded inside.
About Microbot Medical Inc.
Microbot, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
platforms, ViRob and TipCAT, are comprised of two highly advanced
micro-robotic technologies, from which the Company is currently
developing its first two product candidates: the Self Cleaning
Shunt™, or SCS™, for the treatment of hydrocephalus and Normal
Pressure Hydrocephalus, or NPH; and a self-propelling,
semi-disposable endoscope that is being developed initially for use
in colonoscopy procedures. Further information about Microbot
Medical is available at http://www.microbotmedical.com.
The ViRob technology is a revolutionary
autonomous crawling micro-robot which is designed to be controlled
remotely or within the body. Its miniature dimensions allow
it to navigate and crawl in different spaces within the human body,
including blood vessels, the digestive tract and the respiratory
system. Its unique structure is designed to give it the
ability to move in tight spaces and curved passages as well as the
ability to remain within the human body for prolonged time.
To learn more about ViRob please visit
http://www.microbotmedical.com/technology/virob/.
TipCAT is a transformational self-propelled,
flexible, and semi-disposable endoscope providing see & treat
capabilities within tubular lumens in the human body such as the
colon, blood vessels, and the urinary tract. Its locomotion
mechanism is designed to navigate and crawl through natural &
artificial tubular lumens, applying the minimal necessary pressure
to achieve the adequate friction required for gentle, fast, and
safe advancement within the human body. To learn more about
TipCAT visit http://www.microbotmedical.com/technology/tipcat/.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials
or regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contacts:
Analysts and Institutional InvestorsMichael
PolyviouEVC Groupmpolyviou@evcgroup.com 646-445-4800
Individual InvestorsJeremy RoeIntegra
Consulting Group llcjeremy@integracg.net (925) 262-8305
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024